Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice

Shirdast, Hoda; Ebrahimzadeh, Fatemeh; Taromchi, Amir Hossein; Mortazavi, Yousef; Esmaeilzadeh, Abdolreza; Sekhavati, Mohammad Hadi; Nedaei, Keivan; Mirabzadeh, Esmat

doi:10.1007/s12602-020-09684-1

Cited by 19 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [181] L. lactis L7/L12 (Cytoplasm) b — Oral Mice 0.57 (7−6.43) c [182] Cu-Zn SOD (secretory) b — Oral Mice 1.35 (7.1−5.75) c [183] L. lactis (Live or killed) Omp31 (Cell Wall-Anchored) b — Oral or i.p. Mice No results [184] Attenuated S. typhimurium Fusion of L7/L12 and BLS b — Oral Mice Secretory expression: 1.55 (4.44−2.89) c ; Intracellular expression: 1.32 (4.44−3.12) c [185] L7/L12 — i.m. Mice About 1.7 (3.4−1.7) c [186] Ochrobactrum anthropi Cu-Zn SOD CpG i.p.…”

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Prophylactic vaccines have evolved from traditional whole-cell vaccines to safer subunit vaccines. However, subunit vaccines still face problems, such as poor immunogenicity and low efficiency, while traditional adjuvants are usually unable to meet specific response needs. Advanced delivery vectors are important to overcome these barriers; they have favorable safety and effectiveness, tunable properties, precise location, and immunomodulatory capabilities. Nevertheless, there has been no systematic summary of the delivery systems to cover a wide range of infectious pathogens. We herein summarized and compared the delivery systems for major or epidemic infectious diseases caused by bacteria, viruses, fungi, and parasites. We also included the newly licensed vaccines (e.g., COVID-19 vaccines) and those close to licensure. Furthermore, we highlighted advanced delivery systems with high efficiency, cross-protection, or long-term protection against epidemic pathogens, and we put forward prospects and thoughts on the development of future prophylactic vaccines.

show abstract

Section: Bacterial Infectious Diseases and Advanced Delivery Systemsmentioning

confidence: 99%

Prophylactic vaccine delivery systems against epidemic infectious diseases

Pan¹,

Yue

Zhu³

et al. 2021

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Shirdast et al. introduced the Omp31 gene of Brucella abortus into lactococcal immunized mice and the results showed a significant increase in the levels of sIgA, IgA, IgM and IgG antibodies in the mice ( 37 ). In this study, we found that after oral immunization with pPG-612/ L.casei , the levels of IgM and IgT in rainbow trout increased as the immunization time was delayed.…”

Section: Discussionmentioning

confidence: 99%

Immunological Effects of Recombinant Lactobacillus casei Expressing IHNV G Protein and Rainbow Trout (Oncorhynchus mykiss) Chemokine CK6 as an Oral Vaccine

et al. 2022

View full text Add to dashboard Cite

IHNV is a virus that infects salmonids and causes serious economic damage to the salmonid farming industry. There is no specific treatment for the disease caused by this pathogen and the main preventive measure is vaccination, but this is only possible for small groups of individuals. Therefore, it is important to investigate new oral vaccines to prevent IHNV. In this study, the CK6 chemokine protein of rainbow trout and the truncated G protein of IHNV were used to construct a secretory expression recombinant L.casei vaccine for rainbow trout. The results showed that the levels of IgM and IgT antibodies in rainbow trout reached the highest level on the 15th day after the secondary immunization, and the antibodies exhibited high inhibitory activity against viral infection. Furthermore, the expression of relevant cytokines in different tissues was detected and found to be significantly higher in the oral vaccine group than in the control group. It was also found that pPG-612-CK6-G/L.casei 393 could stimulate splenic lymphocyte proliferation and improve mucosal immunity with significant differences between the immunized and control groups. When infected with IHNV, the protection rate of pPG-612-CK6-G/L.casei 393 was 66.67% higher than that of the control group. We found that pPG-612-CK6-G/L.casei 393 expressed and secreted the rainbow trout chemokine CK6 protein and IHNV truncated G protein, retaining the original immunogenicity of rainbow trout while enhancing their survival rate. This indicates that recombinant L.casei provides a theoretical basis and rationale for the development of an oral vaccine against IHNV and has important practical implications for the protection of rainbow trout from IHNV infection.

show abstract

“…Based on the assumption of safety, the development of expression systems in several strains of such species has thrived as of lately. Many and diverse microbial antigens produced in or surface-displayed on lactic acid bacteria have been able to elicit significant immune and often protective responses [96][97][98][99][100][101]. These bacteria do not only serve as microbial cell factories [102,103] but also as vaccine vectors [103,104], for orally and mucosally-administered formulations, as they are able to induce a potent immune response by expressing foreign antigens, while drawing a minimal response against themselves [105][106][107].…”

Section: Bacteriamentioning

confidence: 99%

Recombinant vaccines in 2022: a perspective from the cell factory

et al. 2022

View full text Add to dashboard Cite

The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80’s, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.

show abstract

Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice

Cited by 19 publications

References 46 publications

Prophylactic vaccine delivery systems against epidemic infectious diseases

Prophylactic vaccine delivery systems against epidemic infectious diseases

Immunological Effects of Recombinant Lactobacillus casei Expressing IHNV G Protein and Rainbow Trout (Oncorhynchus mykiss) Chemokine CK6 as an Oral Vaccine

Recombinant vaccines in 2022: a perspective from the cell factory

Contact Info

Product

Resources

About